PKI-179|1197160-28-3|-陌孚医药/Medlife

您当前的位置：

PKI-179

目录号: PL07553 纯度: ≥98.0%

CAS No. :1197160-28-3

商品编号	规格	价格	会员价
PL07553-5mg	5mg	¥4018.00	请登录
PL07553-10mg	10mg	¥6429.00	请登录
PL07553-25mg	25mg	¥12858.00	请登录
PL07553-50mg	50mg	¥20573.00	请登录
PL07553-100mg	100mg	询价	询价
PL07553-200mg	200mg	询价	询价
PL07553-10mM*1mLinDMSO	10mM*1mLinDMSO	¥4323.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	PKI-179
英文名称	PKI-179
英文别名	Urea, N-[4-[4-(4-morpholinyl)-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl]-N'-4-pyridinyl-;1-(4-(4-(3-Oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea;1-[4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2-yl]phenyl]-3-pyridin-4-ylurea;PKI-179
Cas No.	1197160-28-3
分子式	C₂₅H₂₈N₈O₃
分子量	488.54
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

PKI-179 是一种有效的和具有口服活性的双重 PI3K/mTOR 抑制剂，对 PI3K-α，PI3K-β，PI3K-γ，PI3K-δ 和 mTOR 的 IC₅₀ 值分别为 8 nM，24 nM，74 nM，77 nM 和 0.42 nM。PKI-179 还表现出对 E545K 和 H1047R 的活性，IC₅₀ 值分别为 14 nM 和 11 nM。PKI-179 在体内显示出抗肿瘤活性。

生物活性

PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC 50 s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC 50 s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo.

性状

Solid

IC50 & Target[1][2]

PI3Kα 8 nM (IC50) PI3Kβ 24 nM (IC50

体外研究(In Vitro)

PKI-179 inhibits the cell proliferation, with IC50s of 22 nM and 29 nM for MDA361 and PC3 cells, respectively.
PKI-179 shows inhibitory activity against a panel of 361 other kinases, hERG and cytochrome P450 (CYP) isoforms at concentrations up to >30 μM, but does have activity for CYP2C8 (IC50=3 μM). has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

PKI-179 (5-50 mg/kg; p.o. once daily for 40 days) inhibits the tumor growth and is well tolerated in nude mice bearing MDA-361 human breast cancer tumors.
PKI-179 (50 mg/kg; p.o.) results in good inhibition of PI3K signaling in nude mice bearing MDA361 tumor xenografts.
PKI-179 exhibits good oral bioavailability (98% in nude mouse, 46% in rat, 38% in monkey, and 61% in dog) and a high half-life (>60 min) . has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Venkatesan AM, et, al. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5869-73.
[2]. Rehan M. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. J Mol Graph Model. 2015 Nov;62:226-234.

溶解度数据	In Vitro: DMSO : 100 mg/mL (204.69 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation